PILA PHARMA AB (SE:PILA)

:PILA

PILA

PILA PHARMA AB

RESEARCH TOOLSreports

PILA PHARMA AB (PILA) Price & Analysis

1 Followers

PILA Stock Chart & Stats

kr2.20

-kr0.50(-13.33%)

At close: Mar 06 4:00 PM EST

kr2.20

-kr0.50(-13.33%)

Day’s Range― - ―

52-Week Rangekr1.02 - kr3.93

Previous CloseN/A

Volume9.62K

Average Volume (3M)235.52K

Market Cap

kr95.25M

Enterprise Valuekr79.35M

Total Cash (Recent Filing)kr1.08M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.71

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.37

Shares Outstanding45,682,120

10 Day Avg. Volume194,482

30 Day Avg. Volume235,519

Financial Highlights & Ratios

PEG Ratio-0.37

Price to Book (P/B)4.82

Price to Sales (P/S)63.25

P/FCF Ratio-7.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clean Balance SheetA debt-free capital structure with materially higher equity improves solvency and reduces bankruptcy risk, giving management runway and negotiating leverage for partnerships or licensing. Over 2–6 months this supports continued R&D investment without near-term interest burden.

Revenue ReboundA visible rebound in top-line, though small, indicates improving commercial or milestone-related receipts and may reflect progress de-risking the program. Sustained revenue growth would signal better funding optionality and strengthen operating visibility over coming quarters.

Focused Lead AssetA clear, focused pipeline centered on a single lead candidate in large, structural metabolic markets concentrates resources and clarifies regulatory and partnering pathways, making strategic decisions and out-licensing or collaboration discussions more straightforward long term.

Bears Say

Persistent Cash BurnConsistent negative operating and free cash flow forces ongoing external financing and creates runway risk: repeated capital raises dilute shareholders, constrain program timelines, and can delay development milestones if funding conditions tighten over the next several quarters.

Widening Net LossesGrowing annual losses erode equity and signal increasing cash needs to fund operations. This trend reduces financial flexibility, increases reliance on external capital, and can complicate partnership negotiations as counterparties price higher development and execution risk.

No Commercial Revenue; Financing RelianceAs an R&D-stage biotech with no recurring product revenue, the company depends on equity or sporadic non-dilutive funding. This structural dependence risks dilution and timing uncertainty, affecting long-term capital structure and the ability to deliver clinical milestones reliably.

PILA FAQ

What was PILA PHARMA AB’s price range in the past 12 months?

PILA PHARMA AB lowest stock price was kr1.02 and its highest was kr3.93 in the past 12 months.

What is PILA PHARMA AB’s market cap?

PILA PHARMA AB’s market cap is kr95.25M.

When is PILA PHARMA AB’s upcoming earnings report date?

PILA PHARMA AB’s upcoming earnings report date is Aug 20, 2026 which is in 136 days.

How were PILA PHARMA AB’s earnings last quarter?

PILA PHARMA AB released its earnings results on Feb 26, 2026. The company reported -kr0.369 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.369.

Is PILA PHARMA AB overvalued?

According to Wall Street analysts PILA PHARMA AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PILA PHARMA AB pay dividends?

PILA PHARMA AB does not currently pay dividends.

What is PILA PHARMA AB’s EPS estimate?

PILA PHARMA AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PILA PHARMA AB have?

PILA PHARMA AB has 45,682,120 shares outstanding.

What happened to PILA PHARMA AB’s price movement after its last earnings report?

PILA PHARMA AB reported an EPS of -kr0.369 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.83%.

Which hedge fund is a major shareholder of PILA PHARMA AB?

Currently, no hedge funds are holding shares in SE:PILA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PILA PHARMA AB

PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2a clinical trials for type 2 diabetes. PILA PHARMA AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.